Tumor angiogenesis is one of the most prominent mechanisms
driving tumor development and progression. Since its discovery more
than 30 years ago some of the most important signaling pathways
linking specific angiogenic activities of the tumor cells to the
fatal reactions of the patient s vascular system have been
elucidated. As a consequence crucial targets for therapeutic
intervention have been identified and validated.
Based on these efforts and achievements, targeted drug
development programs have been implemented to interfere with tumor
angiogenesis as an attractive strategy in cancer treatment.
As a promising result the first targeted anti-angiogenic drugs
have been approved for a variety of solid metastasizing cancers.
The first generation of these molecules targets the two most
prominent regulatory components of tumor angiogenesis: the vascular
endothelial growth factor (VEGF), produced by tumor cells, and the
VEGF receptor tyrosine kinase, which is expressed on vascular
endothelial cells.
Part 1 of this volume describes the basic mechanisms of tumor
angiogenesis. Beyond the VEGF/VEGF receptor system, additional
tumor-angiogenic systems are presented as new potential targets for
anti-angiogenic therapy. Part 2 reviews the efforts made in
preclinical research to validate new targets and to show efficacy
in animals. Part 3 is entirely devoted to the clinical development
of the novel anti-angiogenic drugs and their current use in
clinical practice."
General
Is the information for this product incomplete, wrong or inappropriate?
Let us know about it.
Does this product have an incorrect or missing image?
Send us a new image.
Is this product missing categories?
Add more categories.
Review This Product
No reviews yet - be the first to create one!